Nigel Stallard

Best Publications

• A randomized trial of epinephrine in out-of-hospital cardiac arrest

  Gavin D. Perkins;Chen Ji;Charles D. Deakin;Tom Quinn

  796
  Citations

• DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial

  Jonathan A. Cook;Steven A. Julious;William Sones;Lisa V. Hampson;Lisa V. Hampson

  356
  Citations

• Optimal Adaptive Designs for Binary Response Trials

  William F. Rosenberger;William F. Rosenberger;Nigel Stallard;Anastasia Ivanova;Cherice N. Harper

  333
  Citations

• Comments on the draft guidance on “Adaptive design clinical trials for drugs and biologics” of the U.S. Food and Drug Administration

  Werner Brannath;Hans Ulrich Burger;Ekkehard Glimm;Nigel Stallard

  287
  Citations

• Sequential designs for phase III clinical trials incorporating treatment selection.

  Nigel Stallard;Susan Todd

  266
  Citations

• HIV self-testing alone or with additional interventions, including financial incentives, and linkage to care or prevention among male partners of antenatal care clinic attendees in Malawi: An adaptive multi-arm, multi-stage cluster randomised trial.

  Augustine T Choko;Elizabeth L Corbett;Elizabeth L Corbett;Nigel Stallard;Hendramoorthy Maheswaran

  221
  Citations

• Effectiveness of a Web-Based Cognitive-Behavioral Tool to Improve Mental Well-Being in the General Population: Randomized Controlled Trial

  John Powell;Thomas Hamborg;Nigel Stallard;Amanda Burls

  210
  Citations

• DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial

  Jonathan A Cook;Steven A Julious;William Sones;Lisa V Hampson;Lisa V Hampson

  183
  Citations

• A group-sequential design for clinical trials with treatment selection.

  Nigel Stallard;Tim Friede

  133
  Citations

• Optimal sample sizes for phase II clinical trials and pilot studies.

  Nigel Stallard

  133
  Citations

• A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information.

  Nigel Stallard

  129
  Citations

• Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART) : a phase 2b, multiarm, double-blind, randomised placebo-controlled trial

  Jeremy Chataway;Jeremy Chataway;Floriana De Angelis;Peter Connick;Richard A Parker

  125
  Citations

• Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review

  Thomas Ondra;Alex Dmitrienko;Tim Friede;Alexandra Graf

  125
  Citations

• A conditional error function approach for subgroup selection in adaptive clinical trials.

  Tim Friede;Nicholas R. Parsons;Nigel Stallard

  117
  Citations

• Sample size determination for phase II clinical trials based on Bayesian decision theory.

  Nigel Stallard

  116
  Citations

• Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis

  Tim Friede;Nicholas R. Parsons;Nigel Stallard;S. Todd

  106
  Citations

• An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several.

  Patrick J Kelly;Nigel Stallard;Susan Todd

  103
  Citations

• Bayesian Graphical Models for Genomewide Association Studies

  Claudio J. Verzilli;Nigel Stallard;John C. Whittaker

  99
  Citations

• Seamless phase II/III designs.

  Nigel Stallard;Susan Todd

  99
  Citations

• A New Clinical Trial Design Combining Phases 2 and 3: Sequential Designs with Treatment Selection and a Change of Endpoint

  Susan Todd;Nigel Stallard

  97
  Citations